Hematologic Cancers

Global Burden of Myeloma Increasing, Access to Treatments Lacking

Global Burden of Myeloma Increasing, Access to Treatments Lacking

By

A new study reveals that an aging world population is the predominant contributor to a 126% increase in age-standardized incidence rates of multiple myeloma from 1990 to 2016.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

By

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

By

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

By

In the phase 3 ARROW study patients with relapsed/refractory multiple myeloma were randomly assigned to receive carfilzomib 27 mg/m2 twice-weekly or 70 mg/m2 once-weekly

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

By

CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.

Subcutaneous Daratumumab Plus CyBorD in Newly-Diagnosed Amyloid Light Chain Amyloidosis

Subcutaneous Daratumumab Plus CyBorD in Newly-Diagnosed Amyloid Light Chain Amyloidosis

Raymond L. Comenzo, MD, discusses his findings at the ASCO 2018 meeting.

Long-Term Follow-Up Results of ZUMA-1 Trial

Long-Term Follow-Up Results of ZUMA-1 Trial

Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.

Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma Treatment Regimens

View treatment regimens for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, including combination therapies with bortezomib and more.

IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom's Macroglobulinemia

IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom's Macroglobulinemia

Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.

Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenstrom Macroglobulinemia

Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenstrom Macroglobulinemia

By

Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

By

Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

By

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

By

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

By

The increase in use of lenalidomide as maintenance treatment emphasizes the need to explore additional treatment options among patients with lenalidomide-refractory multiple myeloma.

Pomalidomide Plus Bortezomib, Dexamethasone Prolongs PFS in Relapsed/Refractory Multiple Myeloma

Pomalidomide Plus Bortezomib, Dexamethasone Prolongs PFS in Relapsed/Refractory Multiple Myeloma

By

Researchers randomly assigned 559 patients with relapsed/refractory multiple myeloma to receive bortezomib and dexamethasone with or without pomalidomide.

Early, Attenuated-Dose Hypomethylating Agent Therapy May Be Effective in Low-Risk MDS

Early, Attenuated-Dose Hypomethylating Agent Therapy May Be Effective in Low-Risk MDS

By

The impact of this attenuated-dose hypomethylating agents among patients with low-risk myelodysplastic syndrome who are transfusion independent requires further investigation.

Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma

Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma

By

Although the findings need to be tested further in clinical trials, this could lead to new targeted therapies with fewer toxicities for patients.

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

By

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL

Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL

By

The efficacy of nelarabine among newly diagnosed patients with T-cell ALL has not been fully explored.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma

Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma

By

Daratumumab is moving from a monotherapy for relapsed and refractory myeloma to a potential frontline player in combination induction regimens. And on the horizon are investigational bispecific antibodies, mAb-drug conjugates, and CAR-T therapies that might offer new advances against what today remains an incurable disease.

Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

By

The impact of dose-intensity reduction in Waldenstrom macroglobulinemia has not been explored.

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

By

Men have approximately double the incidence rate, are more likely to have progressive and treatment-resistant disease, and have a poorer prognosis compared with women with CLL.

Pediatric CML: Life-Long Considerations With TKI Therapy

Pediatric CML: Life-Long Considerations With TKI Therapy

By

Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs